498 related articles for article (PubMed ID: 31873063)
1. Systemic Evaluation of Chimeric LNA/2'-O-Methyl Steric Blockers for Myotonic Dystrophy Type 1 Therapy.
Christou M; Wengel J; Sokratous K; Kyriacou K; Nikolaou G; Phylactou LA; Mastroyiannopoulos NP
Nucleic Acid Ther; 2020 Apr; 30(2):80-93. PubMed ID: 31873063
[TBL] [Abstract][Full Text] [Related]
2. Systemic therapy in an RNA toxicity mouse model with an antisense oligonucleotide therapy targeting a non-CUG sequence within the DMPK 3'UTR RNA.
Yadava RS; Yu Q; Mandal M; Rigo F; Bennett CF; Mahadevan MS
Hum Mol Genet; 2020 Jun; 29(9):1440-1453. PubMed ID: 32242217
[TBL] [Abstract][Full Text] [Related]
3. Short antisense-locked nucleic acids (all-LNAs) correct alternative splicing abnormalities in myotonic dystrophy.
Wojtkowiak-Szlachcic A; Taylor K; Stepniak-Konieczna E; Sznajder LJ; Mykowska A; Sroka J; Thornton CA; Sobczak K
Nucleic Acids Res; 2015 Mar; 43(6):3318-31. PubMed ID: 25753670
[TBL] [Abstract][Full Text] [Related]
4. Systemic delivery of a Peptide-linked morpholino oligonucleotide neutralizes mutant RNA toxicity in a mouse model of myotonic dystrophy.
Leger AJ; Mosquea LM; Clayton NP; Wu IH; Weeden T; Nelson CA; Phillips L; Roberts E; Piepenhagen PA; Cheng SH; Wentworth BM
Nucleic Acid Ther; 2013 Apr; 23(2):109-17. PubMed ID: 23308382
[TBL] [Abstract][Full Text] [Related]
5. Muscleblind-like 1 knockout mice reveal novel splicing defects in the myotonic dystrophy brain.
Suenaga K; Lee KY; Nakamori M; Tatsumi Y; Takahashi MP; Fujimura H; Jinnai K; Yoshikawa H; Du H; Ares M; Swanson MS; Kimura T
PLoS One; 2012; 7(3):e33218. PubMed ID: 22427994
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanisms responsible for aberrant splicing of SERCA1 in myotonic dystrophy type 1.
Hino S; Kondo S; Sekiya H; Saito A; Kanemoto S; Murakami T; Chihara K; Aoki Y; Nakamori M; Takahashi MP; Imaizumi K
Hum Mol Genet; 2007 Dec; 16(23):2834-43. PubMed ID: 17728322
[TBL] [Abstract][Full Text] [Related]
7. Reduced cytoplasmic MBNL1 is an early event in a brain-specific mouse model of myotonic dystrophy.
Wang PY; Lin YM; Wang LH; Kuo TY; Cheng SJ; Wang GS
Hum Mol Genet; 2017 Jun; 26(12):2247-2257. PubMed ID: 28369378
[TBL] [Abstract][Full Text] [Related]
8. Fuchs' Endothelial Corneal Dystrophy and RNA Foci in Patients With Myotonic Dystrophy.
Mootha VV; Hansen B; Rong Z; Mammen PP; Zhou Z; Xing C; Gong X
Invest Ophthalmol Vis Sci; 2017 Sep; 58(11):4579-4585. PubMed ID: 28886202
[TBL] [Abstract][Full Text] [Related]
9. In silico discovery of substituted pyrido[2,3-d]pyrimidines and pentamidine-like compounds with biological activity in myotonic dystrophy models.
González ÀL; Konieczny P; Llamusi B; Delgado-Pinar E; Borrell JI; Teixidó J; García-España E; Pérez-Alonso M; Estrada-Tejedor R; Artero R
PLoS One; 2017; 12(6):e0178931. PubMed ID: 28582438
[TBL] [Abstract][Full Text] [Related]
10. AON-induced splice-switching and DMPK pre-mRNA degradation as potential therapeutic approaches for Myotonic Dystrophy type 1.
Stepniak-Konieczna E; Konieczny P; Cywoniuk P; Dluzewska J; Sobczak K
Nucleic Acids Res; 2020 Mar; 48(5):2531-2543. PubMed ID: 31965181
[TBL] [Abstract][Full Text] [Related]
11. RNA interference targeting CUG repeats in a mouse model of myotonic dystrophy.
Sobczak K; Wheeler TM; Wang W; Thornton CA
Mol Ther; 2013 Feb; 21(2):380-7. PubMed ID: 23183533
[TBL] [Abstract][Full Text] [Related]
12. A flow cytometry-based screen identifies MBNL1 modulators that rescue splicing defects in myotonic dystrophy type I.
Zhang F; Bodycombe NE; Haskell KM; Sun YL; Wang ET; Morris CA; Jones LH; Wood LD; Pletcher MT
Hum Mol Genet; 2017 Aug; 26(16):3056-3068. PubMed ID: 28535287
[TBL] [Abstract][Full Text] [Related]
13. Peptide-conjugated oligonucleotides evoke long-lasting myotonic dystrophy correction in patient-derived cells and mice.
Klein AF; Varela MA; Arandel L; Holland A; Naouar N; Arzumanov A; Seoane D; Revillod L; Bassez G; Ferry A; Jauvin D; Gourdon G; Puymirat J; Gait MJ; Furling D; Wood MJ
J Clin Invest; 2019 Nov; 129(11):4739-4744. PubMed ID: 31479430
[TBL] [Abstract][Full Text] [Related]
14. (CTG)n repeat-mediated dysregulation of MBNL1 and MBNL2 expression during myogenesis in DM1 occurs already at the myoblast stage.
André LM; van Cruchten RTP; Willemse M; Wansink DG
PLoS One; 2019; 14(5):e0217317. PubMed ID: 31116797
[TBL] [Abstract][Full Text] [Related]
15. Identification of Plant-derived Alkaloids with Therapeutic Potential for Myotonic Dystrophy Type I.
Herrendorff R; Faleschini MT; Stiefvater A; Erne B; Wiktorowicz T; Kern F; Hamburger M; Potterat O; Kinter J; Sinnreich M
J Biol Chem; 2016 Aug; 291(33):17165-77. PubMed ID: 27298317
[TBL] [Abstract][Full Text] [Related]
16. MBNL1 and CUGBP1 modify expanded CUG-induced toxicity in a Drosophila model of myotonic dystrophy type 1.
de Haro M; Al-Ramahi I; De Gouyon B; Ukani L; Rosa A; Faustino NA; Ashizawa T; Cooper TA; Botas J
Hum Mol Genet; 2006 Jul; 15(13):2138-45. PubMed ID: 16723374
[TBL] [Abstract][Full Text] [Related]
17. Sense and Antisense DMPK RNA Foci Accumulate in DM1 Tissues during Development.
Michel L; Huguet-Lachon A; Gourdon G
PLoS One; 2015; 10(9):e0137620. PubMed ID: 26339785
[TBL] [Abstract][Full Text] [Related]
18. Staufen1 Regulates Multiple Alternative Splicing Events either Positively or Negatively in DM1 Indicating Its Role as a Disease Modifier.
Bondy-Chorney E; Crawford Parks TE; Ravel-Chapuis A; Klinck R; Rocheleau L; Pelchat M; Chabot B; Jasmin BJ; Côté J
PLoS Genet; 2016 Jan; 12(1):e1005827. PubMed ID: 26824521
[TBL] [Abstract][Full Text] [Related]
19. Recent Progress and Challenges in the Development of Antisense Therapies for Myotonic Dystrophy Type 1.
De Serres-Bérard T; Ait Benichou S; Jauvin D; Boutjdir M; Puymirat J; Chahine M
Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362145
[TBL] [Abstract][Full Text] [Related]
20. Expanded CUG repeats in
van Cruchten RTP; Wieringa B; Wansink DG
RNA; 2019 Apr; 25(4):481-495. PubMed ID: 30700578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
